In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
Seattle, USA-based Alpine Immune Sciences, an immunotherapy company developing innovative treatments for autoimmune and inflammatory diseases, has named Christina Yi its new chief technology officer. 24 August 2023
Biotechnology
Japanese mid-size drugmaker Kyowa Kirin says it has received approval from the Ministry of Health, Labor and Welfare (MHLW) for partial change of approved indication of Lumicef (brodalumab [genetical recombination]) for the treatment of palmoplantar pustulosis (PPP) that respond inadequately to existing therapies. 24 August 2023
Biosimilars
An Expert View from Róbert Wessman, founder and chairman of Icelandic biosimilars company Alvotech and investment fund Aztiq. 23 August 2023
Biotechnology
In the latest reminder about the lingering presence of COVID-19, the US Department of Health and Human Services (HHS) has awarded more than $1.4 billion for Project NextGen to support the development of new tools and technologies to protect against the virus. 23 August 2023
Biotechnology
Bristol Myers Squibb has been granted a new European approval for Opdivo (nivolumab) as a monotherapy in skin cancer. 23 August 2023
Pharmaceutical
Fulcrum Therapeutics saw its shares gain as much as 48.5% to $5.82 pre-market yesterday following an update from the US Food and Drug Administration (FDA). 23 August 2023
Biotechnology
US drugmaker Eli Lilly has announced top-line results from the LIBRETTO-531 study. 23 August 2023
Biotechnology
California, USA-based clinical stage biotech Neuron2 has appointed Andrew Yost as the company’s chief business officer (CBO). 23 August 2023
Biotechnology
The US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data supporting Amgen’s supplemental New Drug Application (sNDA) for the full approval of Lumakras (sotorasib). 23 August 2023
Biotechnology
August is Spinal Muscular Atrophy (SMA) Awareness Month – an opportune time to explore pharmacological advances in the treatment of this autosomal-recessive, progressive neuromuscular disease.1 23 August 2023
Biotechnology
While Geron had hoped for a Priority Review for its rare blood cancer candidate imetelstat, the US regulator has confirmed a standard review will now take place, with a decision due by mid-June next year. 23 August 2023
Biotechnology
Oxford, UK-based techbio innovator Etcembly is coming out of stealth mode, kickstarting the next generation of immunotherapies with a pipeline of best-in-class T cell receptor (TCR) therapeutics designed using generative AI. 23 August 2023
Biotechnology
US pharma giant Pfizer’s Abrysvo has won US approval for use in pregnant women to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through six months of age. 22 August 2023
Pharmaceutical
Exelixis and Ipsen have announced that the Phase III CONTACT-02 pivotal trial met one of two primary endpoints, demonstrating a statistically-significant improvement in progression-free survival (PFS) at the primary analysis. 22 August 2023
Pharmaceutical
Sweden-based IRLAB Therapeutics has secured full global rights ownership of mesdopetam, the company’s leading asset, which was previously out-licensed to French drugmaker Ipsen. 22 August 2023
Biotechnology
The European Commission (EC) has granted conditional marketing authorization (CMA) of Talvey (talquetamab), developed by Janssen Pharmaceuticals. 22 August 2023
Pharmaceutical
Medicines for Malaria Venture (MMV) today revealed that Brazil has become the first malaria-endemic country to approve the use of single-dose tafenoquine (Kozenis) for children aged two years and above in combination with chloroquine. 22 August 2023
Biotechnology
California-based Genesis Therapeutics, a company seeking to use artificial intelligence (AI) to create medicines, has closed an oversubscribed $200 million round of Series B financing. 22 August 2023
Biotechnology
US mRNA specialist Moderna saw its shares close up 9.3% at $111.08 on Monday after the announcement of a collaboration agreement to investigate Shanghai, China-based CARsgen Therapeutics’ investigational Claudin18.2 CAR T-cell product candidate (CT041) in combination with Moderna’s investigational Claudin18.2 mRNA cancer vaccine. 22 August 2023
Biotechnology
US clinical-stage biotech Apogee Therapeutic has appointed Mark McKenna as chairman of its board of directors. 22 August 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze